Buys | $0 | 0 | – |
Sells | $0 | 0 | – |
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; …
Over the last 12 months, insiders at Synaptogenix, Inc. have bought $0 and sold $0 worth of Synaptogenix, Inc. stock.
On average, over the past 5 years, insiders at Synaptogenix, Inc. have bought $165,600 and sold $190,375 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 10,000 shares for transaction amount of $83,000 was made by Silverman Joshua (director) on 2021‑06‑14.
2022-12-16 | Sale | Silverman Joshua | director | 19,012 0.2656% | $1.17 | $22,280 | -30.83% | |
2022-12-16 | Sale | Alkon Daniel L. | President and CSO | 19,688 0.2751% | $1.17 | $23,072 | -30.83% | |
2022-12-16 | Sale | WEINSTEIN ROBERT | Chief Financial Officer | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | |
2022-12-16 | Sale | TUCHMAN ALAN J | Chief Executive Officer | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | |
2022-12-16 | Sale | Singer William S. | director | 27,000 0.3773% | $1.17 | $31,641 | -30.83% | |
2022-12-16 | Sale | SCHECHTER JONATHAN | director | 20,250 0.2829% | $1.17 | $23,731 | -30.83% | |
2022-12-16 | Sale | Bernstein Bruce | director | 22,500 0.3144% | $1.17 | $26,368 | -30.83% | |
2021-06-14 | Silverman Joshua | director | 10,000 0.2577% | $8.30 | $83,000 | -3.58% | ||
2021-06-14 | Alkon Daniel L. | Chief Scientific Officer | 10,000 0.2565% | $8.26 | $82,600 | -3.58% |
Silverman Joshua | director | 38238 2.8207% | $107,066.40 | 1 | 1 | <0.0001% |
Alkon Daniel L. | President and CSO | 35546 2.6221% | $99,528.80 | 1 | 1 | <0.0001% |
$18,881,323 | 88 | -48.96% | $5.9M | |
$296,936 | 37 | -18.12% | $3.46M | |
$960,082 | 17 | -6.29% | $3.37M | |
$1,558,469 | 16 | -26.98% | $4.79M | |
$139,855 | 11 | -32.84% | $5.37M |
Increased Positions | 2 | +28.57% | 12,995 | +510.81% |
Decreased Positions | <1 | -14.29% | 1,005 | -39.5% |
New Positions | <1 | New | 10,844 | New |
Sold Out Positions | 0 | Sold Out | 0 | Sold Out |
Total Postitions | 8 | +14.29% | 14,534 | +471.31% |
Geode Capital Management, Llc | $29.00 | 1.08% | 10,844 | +10,844 | New | 2024-12-31 |
Ubs Group Ag | $9.00 | 0.32% | 3,238 | +2,151 | +197.88% | 2024-12-31 |
Tower Research Capital Llc (Trc) | $1.00 | 0.03% | 266 | -1,005 | -79.07% | 2024-12-31 |
Morgan Stanley | $0 | 0.01% | 90 | 0 | 0% | 2024-12-31 |
Osaic Holdings, Inc. | $0 | <0.01% | 34 | 0 | 0% | 2024-12-31 |
Blackrock, Inc. | $0 | <0.01% | 29 | 0 | 0% | 2024-12-31 |
Acadian Asset Management Llc | $0 | <0.01% | 23 | 0 | 0% | 2024-12-31 |
Bank Of America Corp /De/ | $0 | <0.01% | 10 | 0 | 0% | 2024-12-31 |